Navigation Links
ATL/TV1102 Trial Results Presented at World Congress on Treatment and Research in Multiple Sclerosis
Date:9/21/2008

expected to grow with the introduction of novel treatment options. There remains a high demand for more effective and better tolerated treatments.

About ATL/TV1102 for MS: ATL/TV1102 is an antisense drug discovered by Isis Pharmaceuticals, Inc. and licensed to ANP. Antisense drugs specifically block disease-causing proteins from being produced by interacting with their intended target based on information in the genetic code. ATL/TV1102 is a second-generation antisense inhibitor of CD49d, a subunit of VLA-4 (Very Late Antigen-4). In inflammation, white blood cells (leukocytes) move out of the bloodstream into the inflamed tissue, for example, the CNS in MS, and the lung airways in asthma. The inhibition of VLA-4 may prevent white blood cells from entering sites of inflammation, thereby halting progression of the disease. VLA-4 is a clinically validated target in the treatment of MS. Antisense inhibition of VLA-4 has demonstrated positive effects in a number of animal models of inflammatory disease including MS (Myers et al. J Neuroimmunol 160, p12-24, 2005).

About Antisense Therapeutics Limited: Antisense Therapeutics Limited (ASX: ANP) is an Australian publicly listed biopharmaceutical drug discovery and development company. Its mission is to create, develop and commercialize antisense pharmaceuticals for large unmet markets. ANP has two drugs in development and two drugs in pre-clinical research. ATL/TV1102 (injection) has completed a Phase IIa trial as a potential treatment of multiple sclerosis. ATL1103 is a second-generation antisense drug designed to lower blood IGF-I levels and is entering pre-clinical development as a potential treatment for acromegaly and vision disorders. ATL/TV1102 (inhaled) is at the pre-clinical research stage as a potential treatment for asthma. ATL1101 is a second-generation antisense drug at the pre-clinical research stage being investigated as a potential treatment for prostate cancer. ATL/TV1102 has been licensed to T
'/>"/>

SOURCE Isis Pharmaceuticals, Inc.; Antisense Therapeutics Ltd.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Progen Engages Leading CRO to Assist with Phase 3 Trial of PI-88
2. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
3. Romark Initiates Clinical Trial of Alinia(R) for Chronic Hepatitis C in the United States
4. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
5. Millennium Initiates Clinical Trial to EVOLVE the Treatment of Patients with Newly Diagnosed Multiple Myeloma
6. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
7. Positive Kuvan(TM) Pivotal Phase 3 Trial Results Published in The Lancet
8. Clinical Trial Effectiveness: How Pharmas & Biotechs Save Cost with Savvy Investigator Management
9. TaiGen Biotechnology Successfully Completes Patient Recruitment for Phase II Trial of Nemonoxacin for Treatment of Adult Community Acquired Pneumonia (CAP)
10. Iomai Trial Shows 100 Percent Immune Response in Elderly Subjects Vaccinated With Novel Travelers Diarrhea Patch Vaccine
11. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... DALLAS , Sept. 19, 2014 /PRNewswire-iReach/ ... Chinese Oxybutynin Hydrochloride Industry, 2009-2019 is a ... and Chinese Oxybutynin Hydrochloride industry. The report ... Hydrochloride including its classification, application and manufacturing ... China,s top manufacturers of Oxybutynin Hydrochloride listing ...
(Date:9/19/2014)... 2014  The board of directors of AbbVie Inc. ... dividend of $0.42 per share.  The ... of record at the close of business on Oct. ... global, research-based biopharmaceutical company formed in 2013 following separation ... expertise, dedicated people and unique approach to innovation to ...
(Date:9/19/2014)... , Sept. 19, 2014 Merck (NYSE: MRK ... and Canada , is teaming with celebrity ... Diabetes: Logra Tus Metas , an educational program encouraging Hispanics with ... -- a key treatment goal to help reduce the risk of ... are at a higher risk for developing type 2 diabetes ...
Breaking Medicine Technology:Oxybutynin Hydrochloride Industry 2014-2019 Chinese Forecasts & Analysis 2Oxybutynin Hydrochloride Industry 2014-2019 Chinese Forecasts & Analysis 3Oxybutynin Hydrochloride Industry 2014-2019 Chinese Forecasts & Analysis 4Oxybutynin Hydrochloride Industry 2014-2019 Chinese Forecasts & Analysis 5Celebrity Chef Leticia Moreinos Schwartz Partners with Merck on Desafiando La Diabetes: Logra Tus Metas to Urge Hispanics With Type 2 Diabetes to Get to Their A1C Goal 2Celebrity Chef Leticia Moreinos Schwartz Partners with Merck on Desafiando La Diabetes: Logra Tus Metas to Urge Hispanics With Type 2 Diabetes to Get to Their A1C Goal 3Celebrity Chef Leticia Moreinos Schwartz Partners with Merck on Desafiando La Diabetes: Logra Tus Metas to Urge Hispanics With Type 2 Diabetes to Get to Their A1C Goal 4Celebrity Chef Leticia Moreinos Schwartz Partners with Merck on Desafiando La Diabetes: Logra Tus Metas to Urge Hispanics With Type 2 Diabetes to Get to Their A1C Goal 5
(Date:9/20/2014)... Sept. 19, 2014 (HealthDay News) -- The avian flu ... 2011 could be spread through respiratory drops and therefore ... new study. Although no human illnesses have been ... Jude Children,s Research hospital have discovered natural mutations to ... to travel through the air in droplets. Current ...
(Date:9/20/2014)... New York (PRWEB) September 20, 2014 ... morcellators ( http://www.injurybeacon.com/power-morcellator/ ) in gynecological surgeries ... yet another insurer has announced plans to end ... posted on its website last month, Harrisburg, Pennsylvania-based ... effective November 1, 2014. The insurer said its ...
(Date:9/20/2014)... PA (PRWEB) September 20, 2014 "As a ... in their tanks," said an inventor from Tamaqua, Pa. "The ... mounted on the backs of their chairs. My invention enables ... developed the Kam Oxygen Sensor to make it easier to ... that the user knows when the tank is low. It ...
(Date:9/20/2014)... 20, 2014 RBSEO Services, which has ... companies, has announced it provides an affordable website SEO ... , This announcement would benefit those new and old ... but cannot afford to pay a big amount for ... of their websites in top search results for their ...
(Date:9/20/2014)... Nevada (PRWEB) September 20, 2014 ... extremely successful showing at the PAIN Week conference ... Cosmopolitan Hotel and Casino in Las Vegas from ... MarijuanaDoctors.com primarily attended PAIN Week in the hopes ... as a viable and legitimate tool to treat ...
Breaking Medicine News(10 mins):Health News:Avian Flu In Harbor Seals Could Infect People 2Health News:As Power Morcellator Concerns Grow, Bernstein Liebhard LLP Notes Another Insurer’s Decision to Drop Coverage for Uterine Morcellation 2Health News:As Power Morcellator Concerns Grow, Bernstein Liebhard LLP Notes Another Insurer’s Decision to Drop Coverage for Uterine Morcellation 3Health News:RBSEO Services Announces Affordable Website SEO Service at Only $175 2Health News:MarijuanaDoctors.com Experiences Unprecedented Support and Growth at Pain Week 2014 2
... A new comparison of the procedures to help prevent ... of the neck concludes they are equally effective at ... surgery or a minimally invasive treatment using wire coils ... six percent. Results of the analysis were detailed in ...
... blood test to help diagnose major depressive disorder indicates ... a paper published in the journal Molecular Psychiatry ... reports that a test analyzing levels of nine biomarkers ... without significant false-positive results. "Traditionally, ...
... Reinberg HealthDay Reporter , TUESDAY, Jan. 31 ... to control indigestion and heartburn may put themselves at ... use of these drugs, called proton pump inhibitors (PPIs), ... percent for current or former smokers, the researchers added. ...
... you are a people-pleaser who strives to keep your social ... certain social situations like Super Bowl watch parties. A new ... not, some people eat in an attempt to keep others ... upset the sense of social harmony," says Julie Exline, a ...
... TUESDAY, Jan. 31 (HealthDay News) -- Physicians can boost their chances ... flexible sigmoidoscopy test, which is a less invasive procedure than ... at the value of following up a negative flexible sigmoidoscopy test ... repeat test. However, "you don,t find twice as many [signs ...
... new therapies and data on the relative benefits of ... advance of the fourth annual Genitourinary Cancers Symposium, being ... Marquis in San Francisco, Calif. The results of ... briefing via live webcast): 1) Vigorous Exercise Linked ...
Cached Medicine News:Health News:Stents and surgery for blocked neck arteries are neck-and-neck as lasting stroke prevention 2Health News:Stents and surgery for blocked neck arteries are neck-and-neck as lasting stroke prevention 3Health News:Blood test accurately distinguishes depressed patients from healthy controls 2Health News:Blood test accurately distinguishes depressed patients from healthy controls 3Health News:Heartburn Drugs May Raise Fracture Risk in Older Women 2Health News:Heartburn Drugs May Raise Fracture Risk in Older Women 3Health News:Hold the extra burgers and fries when people pleasers arrive 2Health News:Alternative to Colonoscopy Spots Cancers, Too 2Health News:Research from the 2012 Genitourinary Cancers Symposium highlights new treatments, compares existing therapies for prostate cancer 2
... of doublet objective and high power negative ... 3.0x. The true benefit of this system ... focal clarity is made possible due to ... lightweight aluminum bar and individual interpupillary adjustment ...
Used for maintaining and forming the anterior chamber by the injection and removal of fluids, air miotics, and viscoeastic substances, as well as keeping the cornea moist during surgery. 4 mm from be...
23 gauge cannula (E4969 L) with 0.33 mm aspiration port, curved shaft and polished finish. Includes Teflon irrigating sleeve (E4969 SL). Uses 60 cm (23.6 inches) of silicone tubing (N5941 5). Overall...
... with five legs for extra stability. ... 25" (total vertical travel 6"). 2" ... Comfortable, durable and fire retardant upholstery, ... other colors available by special order. ...
Medicine Products: